BeOne Medicines (ONC) Operating Leases (2019 - 2026)
BeOne Medicines (ONC) posted quarterly Operating Leases of $49.7 million for Q1 2026, down 9.52% year-over-year from $54.9 million in Q1 2025, and down 6.18% quarter-over-quarter from $52.9 million in Q4 2025.
BeOne Medicines (ONC) Operating Leases (2019 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Operating Leases for 8 consecutive years, with $49.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 9.52% year-over-year to $49.7 million; the TTM figure through Mar 2026 stood at $49.7 million (down 9.52% YoY), while the FY2025 annual figure was $52.9 million, up 19.57% from the prior year.
- Operating Leases slipped to $49.7 million in Q1 2026 per ONC's latest filing, from $52.9 million in the prior quarter.
- Across five years, Operating Leases topped out at $54.9 million in Q1 2025 and bottomed at $17.7 million in Q1 2024.
- Historically, Operating Leases has averaged $39.7 million across 5 years, with a median of $40.0 million in 2022.
- Annual changes were most pronounced in 2022 — Operating Leases slumped 46.87% — and 2025, when it jumped 209.76%.
- BeOne Medicines' Operating Leases stood at $34.5 million in 2022, then advanced by 28.06% to $44.2 million in 2023, then gained by 0.17% to $44.3 million in 2024, then gained by 19.57% to $52.9 million in 2025, then fell by 6.18% to $49.7 million in 2026.
- Business Quant data shows ONC's Operating Leases at $49.7 million in Q1 2026, $52.9 million in Q4 2025, and $51.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.20 Mn |
| Mar 31, 2026 | 49.67 Mn |
| Dec 31, 2025 | 52.94 Mn |
| Sep 30, 2025 | 51.39 Mn |
| Jun 30, 2025 | 53.94 Mn |
| Mar 31, 2025 | 54.90 Mn |
| Dec 31, 2024 | 44.28 Mn |
| Sep 30, 2024 | 32.45 Mn |
| Jun 30, 2024 | 35.40 Mn |
| Mar 31, 2024 | 17.72 Mn |
| Dec 31, 2023 | 44.20 Mn |
| Sep 30, 2023 | 25.47 Mn |
| Jun 30, 2023 | 25.82 Mn |
| Mar 31, 2023 | 32.54 Mn |
| Dec 31, 2022 | 34.52 Mn |
| Sep 30, 2022 | 36.90 Mn |
| Jun 30, 2022 | 41.92 Mn |
| Mar 31, 2022 | 39.99 Mn |
| Dec 31, 2021 | 64.97 Mn |
| Sep 30, 2021 | 37.61 Mn |